BRKR
Bruker Corporation Healthcare - Medical Devices Investor Relations →
Bruker Corporation (BRKR) closed at $61.39 as of 2026-09-18, trading 5.7% above its 200-week moving average of $58.08. The stock moved further from the line this week, up from -8.0% last week. The 14-week RSI sits at 58, indicating neutral momentum.
Trading volume is running at 1.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (0.96 ratio) is neutral — neither side is clearly dominating.
Over the past 1315 weeks of data, BRKR has crossed below its 200-week moving average 18 times. On average, these episodes lasted 23 weeks. Historically, investors who bought BRKR at the start of these episodes saw an average one-year return of +25.2%.
With a market cap of $9.4 billion, BRKR is a mid-cap stock. The company generates a free cash flow yield of 1.9%. Return on equity stands at -3.0%. The stock trades at 3.9x book value.
Share count has increased 3.5% over three years, indicating dilution.
Over the past 25.2 years, a hypothetical investment of $100 in BRKR would have grown to $415, compared to $988 for the S&P 500. BRKR has returned 5.8% annualized vs 9.5% for the index, underperforming the broader market over this period.
Free cash flow has been declining at a -54.3% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: BRKR vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After BRKR Crosses Below the Line?
Across 17 historical episodes, buying BRKR when it crossed below its 200-week moving average produced an average return of +32.3% after 12 months (median +29.0%), compared to +14.8% for the S&P 500 over the same periods. 82% of those episodes were profitable after one year. After 24 months, the average return was +62.5% vs +33.7% for the index.
Each line shows $100 invested at the moment BRKR crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. Between earnings dates, FCF is constant — so the score is purely a function of stock price. The levels below show at what prices BRKR would reach each dislocation threshold.
Dislocation Price Levels
Prices where BRKR's Bean Score would hit each σ threshold. Valid until next earnings report: 2026-11-03.
| Level | σ | Price | Signal |
|---|---|---|---|
| Deep Value | +2σ | $51.71 | Unusually cheap — analysis point |
| Value | +1σ | $57.29 | Cheap vs. own history |
| Fair Value | +0σ | $64.23 | Historical mean behavior |
| Expensive | -1σ | $73.08 | Expensive vs. own history |
| Deep Expensive | -2σ | $84.75 | Unusually expensive — analysis point |
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-04 | $0.38 | $0.49 | +27.5% |
| 2026-05-06 | $0.23 | $0.31 | +34.8% |
| 2026-02-12 | $0.65 | $0.59 | -9.8% |
| 2025-11-03 | $0.32 | $0.45 | +38.8% |
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
the write-ups I read Simply Wall St · Visual company reports and write-ups. Free tier covers five reports a month. referral
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are analysis points: prices at which the yield deviation becomes unusual enough to justify the work. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from BRKR's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. Each one is an analysis point, a reason to open the filings. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
BRKR has crossed below its 200-week MA 18 times with an average 1-year return of +25.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2001 | Oct 2001 | 15 | 46.6% | -71.8% | +412.7% |
| Nov 2001 | Nov 2005 | 211 | 81.2% | -73.2% | +237.3% |
| Jan 2006 | Jan 2006 | 1 | 5.8% | +71.2% | +1376.6% |
| Feb 2006 | Feb 2006 | 1 | 0.1% | +74.2% | +1311.6% |
| Feb 2006 | Mar 2006 | 1 | 0.9% | +108.1% | +1340.1% |
| Oct 2008 | Jun 2009 | 32 | 55.6% | +54.7% | +830.1% |
| Jul 2009 | Jul 2009 | 1 | 0.3% | +39.6% | +692.1% |
| Nov 2011 | Nov 2011 | 2 | 8.0% | +13.5% | +434.5% |
| Dec 2011 | Jan 2012 | 3 | 2.1% | +20.4% | +421.9% |
| Jul 2012 | Sep 2012 | 6 | 8.1% | +52.1% | +446.3% |
| Oct 2012 | Nov 2012 | 4 | 9.9% | +62.6% | +423.1% |
| Aug 2015 | Oct 2015 | 7 | 6.5% | +26.3% | +259.8% |
| Oct 2016 | Oct 2016 | 1 | 2.7% | +58.8% | +217.1% |
| Sep 2022 | Oct 2022 | 3 | 9.2% | +26.0% | +17.7% |
| Sep 2023 | Sep 2023 | 1 | 0.7% | +4.7% | +1.2% |
| Oct 2023 | Nov 2023 | 6 | 7.8% | +4.4% | +0.2% |
| May 2024 | Jun 2026 | 108 | 52.6% | -43.8% | -5.4% |
| Aug 2026 | Ongoing | 7+ | 8.2% | Ongoing | +14.9% |
| Average | 23 | — | +25.2% | — |
Frequently Asked Questions
Is BRKR below its 200-week moving average?
No. Bruker Corporation (BRKR) is currently 5.7% above its 200-week moving average of $58.08. It would need to fall to $58.08 to cross below the line.
What is BRKR's 200-week moving average price?
Bruker Corporation's 200-week moving average is $58.08 as of 2026-09-18. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when BRKR drops below its 200-week moving average?
BRKR has crossed below its 200-week moving average 18 times in our data. On average, buying at that moment produced a one-year return of +25.2%. These dips have historically been decent entry points. These episodes lasted 23 weeks on average.
Is BRKR a good value right now?
Here's what our data says about BRKR as of 2026-09-18: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 58. Free cash flow yield is 1.9%. Return on equity is -3.0%. Price-to-book is 3.9x. This is not a buy or sell recommendation — always do your own research.
How does BRKR compare to the S&P 500?
Over the past 25.2 years, $100 invested in BRKR would have grown to $415, compared to $988 for the S&P 500. That's 5.8% annualized vs 9.5% for the index. BRKR has underperformed the broader market over this period.
Does BRKR pay a dividend?
Yes. Bruker Corporation currently pays a dividend yield of 32.00%.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-09-18